Gain Therapeutics, Inc.
NASDAQ:GANXBiotechnology
+$0.06 today
- Market cap
- $50.33M
- Beta
- 0.16
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$0.50
Volume 4.26M
Average 0.64M
GANX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Gain Therapeutics, Inc.NASDAQ: GANX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$5.4M, compared with -$4.41M a year earlier. Trailing-twelve-month EBITDA was -$20.2M.
Context
- EBITDA grew in size in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 4 analysts of -$14.41M (+25.0%) for the fiscal year ending Dec 2026, a step up from the +3.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.4M-21.7% QoQ
- Last fiscal yearDec 2025
- -$19.21M+3.0% YoY
- LTMMar 2026
- -$20.2M+0.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -22.6% | -6.5% | +16.1 pp |
| 1 year | +3.0% | +25.0% | +22.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (19.21M) USD
- Year-over-year change
- +3.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (19.21M) | +3.0% |
| FY2024 | 2024-12-31 | (19.79M) | +10.5% |
| FY2023 | 2023-12-31 | (22.1M) | -26.8% |
| FY2022 | 2022-12-31 | (17.43M) | -25.7% |
| FY2021 | 2021-12-31 | (13.87M) | — |
EBITDA vs competitors
How GANX compares with its peers on the latest reported figures
- GANX's LTM Mar 2026 EBITDA of -$20.2M is the 3rd highest of the 9 companies compared; the peer median is -$35.39M.
- Its year-over-year change of +0.1% is the 5th highest of 8, against a peer median of +4.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $148.02M | +264.5% | — | 223.7% | |
| LTM Apr 2026 | -$7.89M | +18.5% | — | 437.7% | |
| LTM Mar 2026 | -$20.2M | +0.1% | — | — | |
| LTM Mar 2026 | -$23.33M | -0.3% | — | 1017.5% | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$34.71M | -256.5% | — | — |
| LTM Jun 2024 | -$36.06M | — | — | 4420.7% | |
| LTM Mar 2026 | -$38.33M | -3.1% | — | — | |
| LTM Mar 2026 | -$102.73M | +7.3% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding GANX) | -$35.39M | +4.8% | — | 1017.5% | |
Competitors are the stored peer set for GANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 164.99K | 140.11K | 55.18K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 164.99K | 140.11K | 55.18K | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 7.16M | 8.38M | 11.52M | 10.79M | 10.21M |
| Selling, General & Admin | 6.83M | 9.54M | 10.79M | 9.56M | 8.5M |
| Operating Expenses | 13.99M | 17.92M | 22.31M | 20.35M | 18.71M |
| Depreciation & Amortization | 15.48K | 64.17K | 83.58K | 84.07K | 94.05K |
| EBITDA | (13.87M) | (17.43M) | (22.1M) | (19.79M) | (19.21M) |
| EBITDA Margin | -8407.0% | -12443.0% | -40059.2% | — | — |
| Operating Income | (13.83M) | (17.78M) | (22.25M) | (20.35M) | (18.71M) |
| Operating Margin | -8379.8% | -12688.1% | -40328.3% | — | — |
| Interest Income | 12.5K | 375.36K | 494.23K | 357.1K | 244.39K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (60.43K) | 279.28K | 64.89K | 476.22K | (589.28K) |
| Income Before Tax | (13.89M) | (17.5M) | (22.19M) | (19.87M) | (19.3M) |
| Pre-Tax Margin | -8416.4% | -12488.8% | -40210.7% | — | — |
| Income Tax Expense | 4.01K | 92.98K | 79.28K | 536.82K | 861.12K |
| Net Income | (13.89M) | (17.59M) | (22.27M) | (20.41M) | (20.16M) |
| Net Margin | -8418.9% | -12555.1% | -40354.3% | — | — |
| EPS (Basic) | (1.37) | (1.48) | (1.71) | (0.89) | (0.61) |
| EPS (Diluted) | (1.37) | (1.48) | (1.71) | (0.89) | (0.61) |
| Weighted Avg Shares | 10.17M | 11.88M | 13.01M | 22.88M | 32.97M |
| Weighted Avg Shares (Diluted) | 10.17M | 11.88M | 13.01M | 22.88M | 32.97M |
Gain Therapeutics, Inc.
NASDAQ:GANX
Intrinsic Alpha fair value
Locked
Current Price
$1.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.